COVID-19 Impact on bioM?rieux SA’s Revenue and Operations (Medical Devices)
BioM?rieux, formerly B-D Merieux, is a biological technology company which designs, develops and produces a wide range of in vitro diagnostics solutions, headquartered in France with global manufacturing and a huge network of distributors. BioM?rieux’s product range includes solutions for in vitro diagnostics, such as Reagents, Software, and Systems and Services, mainly for the diagnosis of infectious diseases. BioM?rieux also deals with industrial microbiology, agricultural-food industry, cosmetics, and pharmaceutical products. The report, COVID-19 Impact on bioM?rieux SA’s Revenue and Operations (Medical Devices) presents a deep dive analysis into how bioM?rieux SA is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.
Deep dive analysis into how bioM?rieux SA is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.
- BioM?rieux experienced unprecedented 2020 Q1 revenue growth, with an organic growth of 21.5%, driven by unprecedented demand for its molecular biology products used in COVID-19 testing, specifically its two FDA emergency use authorized COVID-19 real-time PCR tests: SARS-CoV-2 R-GENE? test and BIOFIRE? COVID-19 test.
- Negative business impact of COVID-19 was seen in the final weeks of Q1 in immunoassays, and are expected to grow over the following months.
- BioM?rieux revenues are expected to continue growing spurred on by its COVID-19 respiratory panel test, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2.
The report provides a comprehensive analysis of the impact of COVID-19 on bioM?rieux SA -
- It provides insights on bioM?rieux SA’s exposure to the regions and businesses impacted by the COVID-19 outbreak.
- It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.
Reasons To Buy
- An overview of how bioM?rieux SA will be affected by the COVID-19 pandemic.